ClinicalTrials.Veeva

Menu

A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With the TRUPULSE™ Generator for Treatment of Ventricular Arrhythmias (DEVA)

Biosense Webster logo

Biosense Webster

Status

Enrolling

Conditions

Arrhythmias, Cardiac

Treatments

Device: Radiofrequency/Pulsed Field Ablation System

Study type

Interventional

Funder types

Industry

Identifiers

NCT07727057
BWI202601 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to collect information about how safe Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) catheter with TRUPULSE™ Generator is and how effective a specific procedural workflow is when this ablation system is used to treat ventricular arrhythmias. The main aims of this study are to see whether the abnormal heart rhythm can be successfully treated while maintaining a specific procedural workflow with the catheter and generator during the cardiac ablation and to monitor participant safety after the procedure by checking if the participant has any complications.

Enrollment

90 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Participant is planned for a catheter ablation procedure to ablate either: (a) Premature ventricular complexes (PVCs); (b) Sustained monomorphic ventricular tachycardia (VT), including sustained monomorphic ischemic ventricular tachycardia (SMIVT) or sustained monomorphic non-ischemic ventricular tachycardia (SMNIVT), with one or more documented spontaneous episodes of symptomatic sustained monomorphic ventricular tachycardia within 3 months that required device therapy (shock or anti-tachycardia pacing), external cardioversion, escalated antiarrhythmic therapy, and/or hospitalization. Documented episodes will be assessed by review of electrocardiographic data.
  2. Age greater than or equal to 18 years
  3. Willing and capable of providing consent
  4. Able and willing to comply with all pre-, post-, and follow-up testing and requirements
  5. For participants with sustained monomorphic ventricular tachycardia (SMIVT or SMNIVT): participant must have an implantable cardioverter defibrillator (ICD) already implanted before the ventricular tachycardia ablation procedure, or implantation must be planned during or soon after the ablation procedure, during the same hospital admission

Exclusion criteria

  1. Incessant ventricular arrhythmia (VA) necessitating hemodynamic support prior to the ablation procedure
  2. Polymorphic ventricular tachycardia, unstable ventricular tachycardia, or ventricular fibrillation (VF)
  3. Idiopathic VTs
  4. Suspected reversible cause of VA (example, electrolyte abnormalities, thyroid disease, drug induced arrhythmia)
  5. VAs that are thought to be from channelopathies
  6. Severely compromised left ventricular ejection fraction (LVEF) (less than [<] 20 percentage [%])
  7. Uncontrolled heart failure or New York Heart Association (NYHA) Class IV
  8. Pre-procedure stimulation protocol anticipated to be unsafe at the time of the screening visit (e.g., hemodynamically unstable participants, participants with ventricular fibrillation), per Site Investigator discretion
  9. Previous Percutaneous Coronary Intervention (PCI) / Myocardial Infarction (MI) within the past 2 months
  10. Unstable angina pectoris within the past 6 months.
  11. Presence of intracardiac thrombus on pre-ablation imaging
  12. Presence of a condition that precludes vascular access (such as inferior vena cava [IVC] filter in case of anterograde approach)
  13. Epicardial mapping or ablation already anticipated or planned at the time of the screening visit (that is, pre-planned epicardial approach before index VA ablation per protocol)
  14. History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  15. Contraindication to contrast agents.
  16. Life expectancy < 6 months, including advanced heart failure or terminal illness (at the discretion of the Investigator)
  17. Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 6 months
  18. Previous VA ablation within 6 months
  19. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the clinical investigation
  20. Significant congenital anomaly or medical problem that in the opinion of the principal Investigator would preclude enrollment in the study
  21. Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions For Use (IFU)
  22. Ventriculotomy or atriotomy within the preceding 8 weeks
  23. Presence of myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
  24. Prosthetic valves
  25. Acute illness, active systemic infection, or sepsis
  26. Current enrollment in an investigational study evaluating another device, biologic, or drug
  27. Categorized as vulnerable population and requiring special treatment with respect to safeguards of well-being

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

90 participants in 1 patient group

Radiofrequency/Pulsed Field Ablation
Experimental group
Description:
Participants undergoing catheter ablation for the management of premature ventricular complexes (PVC), sustained monomorphic ischemic ventricular tachycardia (SMIVT) and sustained monomorphic non-ischemic ventricular tachycardia (SMNIVT) will undergo catheter ablation using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) catheter in combination with the TRUPULSE™ generator, with radiofrequency and pulsed field energy delivered primarily as radiofrequency (RF)/pulsed field (PF) stacking applications according to the study procedural workflow.
Treatment:
Device: Radiofrequency/Pulsed Field Ablation System

Trial contacts and locations

7

Loading...

Central trial contact

Katie Steenackers, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems